Accelerating global antibacterial innovation

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, a leading cause of death around the world. The CARB-X portfolio is the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics and other products. CARB-X is the only global partnership that integrates solutions for the prevention, diagnosis and treatment of life-threatening bacterial infections, translating innovation from basic research to first-in-human clinical trials.

CARB-X is funded by a global consortium of governments and foundations. CARB-X headquarters are located at Boston University.

The CARB-X 2024 funding round has four distinct themes as described below.

For more details: https://carb-x.org/apply/funding-themes/